US Patent 10,585,106: Incipient Preeclampsia Triggered by Sialyl Lewis Antigen X and Treated With hCG
US10,585,106 claims a pregnancy biomarker-driven method: measure sialyl Lewis antigen X (SLeX) at about 10 weeks gestation or earlier, identify patients with SLeX at ≥ about 22.4% above normal control, then administer human chorionic gonadotropin (hCG) to treat incipient preeclampsia. Dependent claims add pre-management steps, decision rules using higher SLeX thresholds, and administration specifics (including recombinant hCG, IV dosing, and dose ranges).
This analysis breaks down what the claims cover, what they likely require in practice, how enforceability typically plays out for this kind of method-of-treatment patent, and where the landscape pressure points sit.
What does the patent actually claim (scope and mandatory steps)?
Independent claim 1: biomarker threshold + timed pregnancy window + hCG administration
Claim 1 requires a clinician to perform all three core elements:
- Test SLeX level in a human patient-subject at about 10 weeks of pregnancy or earlier.
- Call the patient positive if the SLeX level is ≥ about 22.4% above a normal control level.
- Treat with hCG: administer a therapeutically effective amount of human chorionic gonadotropin “thereby treating” incipient preeclampsia.
Key scoping implications:
- The method is highly constrained by timing (10 weeks or earlier).
- It is tied to a specific biomarker cut-point (22.4% above normal controls).
- It is tied to a specific therapeutic agent class (hCG), but the claim does not lock the molecule to a particular formulation in claim 1 (that happens in dependent claims).
- It is written as a clinical decision-and-treat algorithm. If a party administers hCG based on another marker, or after a later gestational time, they can fall outside claim 1.
Dependent claim 2: “managing for preeclampsia” prior to hCG
Claim 2 adds an additional mandatory pre-step:
- Prior to administering hCG, “managing” the patient for preeclampsia.
The claim does not specify what managing entails. That creates both flexibility and enforceability risk:
- For enforcement, a patentee must show the accused clinician’s pre-hCG care fits the claim’s “managing” language.
- For design-around, a competitor might argue the pre-hCG actions were not “management” for preeclampsia, though in obstetrics many actions could be characterized that way.
Dependent claim 3: a second decision rule using sum levels and a 30% threshold
Claim 3 modifies the “managing” step with a quantitative rule:
- Managing comprises determining whether the sum of the levels of SLeX determined in steps is ≥ about 30% above the sum of levels determined in the other step.
This claim’s logic is likely a drafting artifact risk. It references step (a) again and compares sums of levels from “step (a) is at or greater than about 30% above the sum of the levels determined in step (b).” In claim 1, step (b) is a decision threshold, not a second measurement. Practically, this claim may correspond to:
- repeated measurement(s) and summation, or
- another structured measurement regime described in the specification.
For landscape purposes, claim 3 increases differentiation from claim 1 by adding a specific decision metric, but it may also be harder to prove exactly in litigation if the method is ambiguous or depends on how the patent’s workflow is interpreted.
Dependent claims 4–7: molecule identity, route, and dose range
Claim 4:
Claim 5:
- hCG is administered intravenously.
Claim 6:
- dose is about 50 IU to about 500 IU.
Claim 7:
- narrower dose band: about 100 IU to about 200 IU.
These dependent claims matter for both enforceability and freedom-to-operate (FTO):
- If a product or protocol uses urinary hCG, it may avoid claim 4 while still risking claim 1.
- If a party uses subcutaneous or another route, it avoids claim 5 while still risking claim 1.
- If dosing sits outside 50–500 IU, it avoids claim 6 while still risking claim 1.
- If dosing sits outside 100–200 IU, it avoids claim 7 while still risking claims 1–6.
What are the likely novelty and obviousness pressure points?
This patent’s novelty is concentrated in two linked propositions:
- SLeX (sialyl Lewis antigen X) in early pregnancy at or before ~10 weeks identifies patients at risk of incipient preeclampsia using a defined percent-above-normal cut-point (22.4% above controls).
- Administering hCG based on that biomarker result prevents or treats incipient preeclampsia.
A challenger would typically attack novelty and nonobviousness in three ways: biomarker-as-predictor, therapy-as-treatment, and the combination as an obvious substitution.
Pressure point A: Are SLeX levels known early in pregnancy as a risk marker?
If prior art already discloses SLeX measurement in early pregnancy and links it to preeclampsia risk (or another placental disorder), then claim 1’s biomarker portion may be obvious even if the exact cut-point differs.
Even if the exact 22.4% threshold is not disclosed, challengers can argue:
- threshold optimization is routine,
- patient stratification is known,
- and percent-above-control formatting is a common way to express cut-points.
Pressure point B: Is hCG known for preventing or treating preeclampsia?
If prior art discloses hCG for preeclampsia (or placental insufficiency syndromes) then claim 1’s therapeutic part is not novel.
In that scenario, the only likely novelty remaining is the specific biomarker-triggered patient selection and timing.
Pressure point C: Is biomarker-triggered hCG dosing in incipient preeclampsia an obvious combination?
When both components are known separately, examiners and challengers often frame the combination as an obvious trial of a known therapy in a known at-risk group.
To defend against that, the patent must support:
- a causal link between SLeX elevation and the disease mechanism targeted by hCG, and
- a non-trivial relationship between the chosen threshold and therapeutic success.
The claim language itself does not express mechanism; it is an algorithmic clinical method. That structure makes it easier to attack using general “predictability” arguments unless the specification provides hard empirical evidence tied to the exact cut-point and dosing window.
How enforceable is a clinical decision method claim like this?
Enforcement practicality
For method claims, enforceability often depends on whether the accused party performs each step in the claimed order or within the “thereby treating” logic.
In healthcare, that creates evidentiary issues:
- SLeX measurement must occur at or before about 10 weeks.
- There must be a documented determination of “≥ 22.4% above normal control.”
- There must be hCG administration with a dosing regimen that falls within “therapeutically effective amount” (and within narrower limits for dependent claims).
Order and characterization disputes
The claims do not specify the ordering beyond step (a) then step (b) then step (c). That is clear in claim 1.
But claim 2 introduces a characterization dispute:
- What counts as “managing said patient-subject for preeclampsia” before hCG?
Common obstetric risk management steps could be argued to fall inside or outside that phrase depending on what is done and how it is labeled in clinical records.
Dependent claim narrowing as both protection and vulnerability
Dependent claims (recombinant hCG, IV route, and specific IU bands) can help provide fallback positions, but they also create potential design-around:
- Many legitimate clinical protocols differ in route and dosing.
- If competitors use hCG outside the IU bands or use different formulations, they could avoid the dependent claims, leaving only the broader claim 1 (which still may be at risk if SLeX cut-point or timing is not followed).
Patent landscape implications for R&D and investment
Where this claim likely sits in competitive space
This patent is in a narrow intersection of:
- an early pregnancy biomarker (SLeX) used for risk stratification, and
- a pregnancy hormone therapy (hCG) used for disease prevention or early intervention.
That intersection has two consequence sets:
- If the field already uses SLeX for early risk stratification, then claim 1 could be challenged as obvious even if the threshold is not identical.
- If the field already uses hCG for pregnancy complications, then claim 1 could be challenged as obvious even if SLeX is not used as a trigger.
Either way, the strongest defense usually depends on:
- prior art absence of either component, or
- evidence that the combination and threshold yields unexpected results.
Design-around vectors implied by the claim text
Even without knowing the full specification, the claim structure identifies predictable ways to reduce infringement risk:
- Change the biomarker decision rule: use SLeX but with a different threshold or different normalization method (not “% above a normal control level” in the same way).
- Change timing: measure SLeX after 10 weeks (or use “earlier” than 10 weeks inconsistently to avoid the “about 10 weeks” language).
- Change therapy: use a different agent (or do not use hCG).
- Change formulation/route: avoid recombinant hCG or avoid IV administration.
- Change dose bands: operate outside 50–500 IU or 100–200 IU.
These are not legal conclusions, but they are direct consequences of how dependent claims constrain the independent method.
Critical reading of the claim language for litigation leverage
“about 10 weeks” and “about 22.4% above”
The claim uses “about” for both the gestational time and the percent threshold. That broadens literal scope but also gives challengers a tool:
- “about” can be attacked as indefinite or as an elastic boundary if the specification does not define how “about” is operationalized (measurement variability, normal control definitions, assay platforms).
“normal control level” ambiguity
Claim 1 depends on “normal control level.” If multiple control references exist (different cohorts, assays, labs), the threshold could be interpreted differently. In litigation, the normalization approach becomes a battleground:
- what is the “normal control level” baseline used for the patient?
- is it within the scope of the patent’s normal control definition?
“therapeutically effective amount”
This phrase is broad by design. It also creates enforcement friction:
- In a dispute, a patentee must connect the administered dose to a therapeutic effect for incipient preeclampsia.
- Defendants can argue the amount was not “therapeutically effective” in the incipient preeclampsia context, particularly if used for another obstetric indication.
Dependent dose claims partially resolve that, but only if the accused administration fits the IU bands.
Key takeaways
- US10,585,106 is an algorithm patent: measure early SLeX, stratify patients using a defined ≥22.4% above normal criterion, then administer hCG to treat incipient preeclampsia.
- Dependent claims create layered narrowing for recombinant hCG, IV route, and specific IU bands (50–500; 100–200).
- The enforceability focus is step completion and documentation: early timing, the biomarker threshold decision, then hCG administration.
- The strongest validity risks cluster around prior art for SLeX as an early risk marker, prior art for hCG in preeclampsia, and obvious combination arguments that a known treatment is applied to a known-risk group.
- Practical design-around pathways are built into the claim constraints: biomarker threshold/timing changes, non-hCG therapy, route/formulation changes, or dosing outside the dependent IU bands.
FAQs
1) What is the core novelty of US10,585,106?
The combination of early (about 10 weeks) SLeX measurement using a ≥22.4% above normal control threshold to select patients, followed by hCG administration for incipient preeclampsia.
2) What must be done first for infringement under claim 1?
A clinician must determine SLeX level at about 10 weeks or earlier, then determine it meets ≥22.4% above normal, then administer hCG.
3) Do the dependent claims cover recombinant hCG and IV dosing?
Yes. Dependent claims specify recombinant hCG (claim 4) and intravenous administration (claim 5).
4) What dose ranges are specified in the claims?
The dependent claims specify about 50 IU to about 500 IU (claim 6) and a narrower about 100 IU to about 200 IU (claim 7).
5) What is the role of claim 2 and claim 3?
Claim 2 requires managing for preeclampsia prior to hCG. Claim 3 further constrains that management using a SLeX sum-based rule and a ≥ about 30% threshold.
References
- United States Patent US10,585,106. (n.d.). Claims as provided by user.
